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The Lancet
Reports of trials must conform to CONSORT 2010 guidelines, and should be submitted with their protocols. All accepted Articles should include a link to the full study protocol published on the authors' institutional website.
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To help authors demonstrate that their findings are faithful to their research protocol, The Lancet, The Lancet Oncology, and The Lancet Neurology offer to publish links to the full study protocol on the authors' institutional website.
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The Lancet Oncology
Reports of trials must conform to CONSORT 2010 guidelines, and should be submitted with a full protocol in English, or, with the full protocol and a synopsis in English including details of enrolment criteria, outcomes/endpoints, and statistical considerations. All accepted Articles should include a link to the full study protocol published on the authors' institutional website 4
3 JAMA Authors of manuscripts reporting clinical trials must submit trial protocols (including the complete statistical analysis plan) along with their manuscripts. If the manuscript is accepted, the protocol will be published as an online supplement.
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Journal of Clinical Oncology
JCO believes that for the editors and reviewers to properly peer review a submission, as well as for readers to thoroughly interpret an article, a redaction of the protocol for all randomized phase II and III studies must be provided. This applies to reports of primary planned endpoints of the study, as well as planned or unplanned subset analyses. It is the responsibility of the authors to submit only the following sections (although submission of the full protocol would be acceptable as well). The information provided must reflect the most recent, revised version of the protocol.
Selection of patients, including both eligibility and ineligibility criteria Schema and treatment plan, including administration schedule Rules for dose modification Measurement of treatment effect including response criteria, definitions of response and survival, and methods of measurement Reasons for early cessation of trial therapy Objectives and entire statistical section (including endpoints) Authors should upload this material as a Supplemental File. It will be available to the editors and reviewers during the peer review process and, if your manuscript is accepted, will be published online. Abbreviation: DFS, disease-free survival; RFS, relapse-free survival; EFS, event-free survival; OS, overall survival; TTP, time to progression; PFS, progression-free survival; FFS, failure-free survival; NA, not applicable. * 1 denotes protocol-defined primary endpoint reported as non-primary endpoint in publication; 2 denotes protocol-defined primary endpoint omitted in publication; 3 denotes protocol-defined non-primary endpoint reported as primary endpoint in publication; 4 denotes different terminology of primary endpoint.
Supplementary
Supplementary Table 4: Discrepancies of primary endpoints between registrations and protocol
Variable
No.(%) of Trials (N = 209)
Trials with discrepancies of primary endpoints between registrations and protocols * 16 (7.7) Protocol-defined primary endpoint registered as non-primary endpoint 2 (1.0) Protocol-defined primary endpoint omitted in registrations 9 (4.3) Protocol-defined non-primary endpoint registered as primary endpoint 9 (4.3) Different terminology of primary endpoint † 1 (0.5) * Some studies had multiple types of discrepancies †Two different terms were used for the primary endpoint in the protocol and the registration, but the definition of the endpoints was similar (eg, failure-free survival in protocol, progression-free survival in registration). Abbreviation: OS, overall survival; PFS, progression-free survival; DFS, disease-free survival; EFS, event-free survival; TTP, time to progression; FFS, failure-free survival; NA, not applicable. * 1 denotes protocol-defined primary endpoint registered as non-primary endpoint; 2 denotes protocol-defined primary endpoint omitted in registration; 3 denotes protocol-defined non-primary endpoint registered as primary endpoint; 4 denotes different terminology of primary endpoint.
Supplementary
